Clinigence Holdings Inc (NUTX)
NASDAQ:NUTX
Top Page
Clinigence Holdings
(NASDAQ:NUTX)
Select Model
Select Model
Rating:64Neutral
Price Target:
$102.00
▼(-44.60% Downside)
Action:ReiteratedDate:03/24/26
The score is driven primarily by solid financial performance (notably strong 2025 operating cash flow and improved profitability) and generally constructive earnings-call guidance/capital allocation. These positives are meaningfully offset by weak technicals (bearish trend and momentum) and balance-sheet/IDR-related volatility risks, while valuation is only moderately supportive.
Positive Factors
Operating Cash Generation
Sustained operating cash flow (~$248M in 2025) with FCF roughly equal to net income demonstrates the business can internally fund growth, repurchases and working capital. Durable cash conversion supports investment flexibility and cushions the company through cyclical or regulatory shocks.
Negative Factors
Elevated Leverage
A non-conservative capital structure leaves limited downside protection if operating performance softens. Higher leverage increases interest and refinancing sensitivity, constrains optionality for acquisitions or opportunistic investment, and can amplify earnings volatility under stress.
Read all positive and negative factors
Positive Factors
Negative Factors
Operating Cash Generation
Sustained operating cash flow (~$248M in 2025) with FCF roughly equal to net income demonstrates the business can internally fund growth, repurchases and working capital. Durable cash conversion supports investment flexibility and cushions the company through cyclical or regulatory shocks.
Read all positive factors
Clinigence Holdings (NUTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$703.25M
Dividend YieldN/A
Average Volume (3M)205.35K
Price to Earnings (P/E)15.6
Beta (1Y)2.32
Revenue Growth236.03%
EPS GrowthN/A
CountryUS
Employees800
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)1.69
Shares Outstanding6,968,350
10 Day Avg. Volume200,740
30 Day Avg. Volume205,349
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)3.35
Price to Sales (P/S)1.26
P/FCF Ratio4.49
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit1.73
Enterprise Value/Ebitda2.75
Forecast
1Y Price Target
$225.00Price Target Upside22.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)19.78
Revenue Forecast (FY)$989.61M
Clinigence Holdings Business Overview & Revenue Model
Company Description
Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, incl...
Clinigence Holdings Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive long‑term operational and financial story—very strong full‑year revenue growth (+82.4%), major margin and cash‑flow improvements, profitable and expanding IPAs, high patient satisfaction, and disciplined capital allocation. The principal negatives were a material, timing‑driven Q4 revenue/earnings hit from a CMS‑driven IDR true‑up and a large one‑time stock‑based compensation charge; these items created quarter volatility but appear to be nonrecurring or better understood by management. Given the substantial year‑over‑year improvements in revenue, adjusted EBITDA, cash flow and margins that outweigh the one‑time/quarterly headwinds and controllable operational initiatives underway, the overall sentiment is positive.Positive Updates
Record Full-Year Revenue Growth
Total revenue of $875.3M for FY2025, up 82.4% from $479.9M in FY2024, driven by hospital division expansion and stronger collections.
Negative Updates
Material Q4 Revenue Decline Due to One-Time Arbitration True-Up
Fourth quarter 2025 revenue fell to $151.7M, a 41.1% decline vs Q4 2024, primarily driven by a one-time $55M cumulative true-up related to 18,950 arbitration/IDR claims deemed ineligible (periods July 2024–Dec 2025). Management estimates Q4 adjusted revenue excluding the true-up would be ~$206.7M.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Full-Year Revenue Growth
Total revenue of $875.3M for FY2025, up 82.4% from $479.9M in FY2024, driven by hospital division expansion and stronger collections.
Read all positive updates
Company Guidance
Management's forward guidance emphasized disciplined, profitable growth with four capital priorities — share repurchases (completed $25M program and authorized an additional $25M), growth at existing hospitals (ER/inpatient volume and revenue‑per‑patient initiatives), IPA/Population Health expansion (40,000 members today; launching IPAs in Dallas and San Antonio in 2026) and a capital‑efficient real‑estate play (develop/own through stabilization with potential sale‑leasebacks). They expect three hospital openings in 2026 (Jacksonville, West Little Rock, San Antonio) with ~4 more in 2027, while operating 27 hospitals across 12 states today; operational targets include enterprise tele‑hospitalist coverage in the coming year. Key metrics to monitor: cash $185.6M, net cash from operations $248.1M (12 months), total revenue $875.3M (+82% YoY), adjusted EBITDA $259.6M (+152.6% YoY), hospital visits 188,279 (+11.8% YoY), IDR submission rate ~50–60% (historically 60–70%), prevail rate >85%, collection rate >85%, arbitration cost ~26% of arbitration revenue, and an ineligible IDR rate ~8% (vs ~19% national); management characterized the Q4 ~$55M IDR true‑up as a one‑time timing issue and urged focus on full‑year results.Clinigence Holdings Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
58
Neutral
Cash Flow
85
Very Positive
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 875.26M | 479.95M | 247.65M | 219.29M | 331.53M |
| Gross Profit | 444.28M | 196.26M | 34.77M | 15.42M | 179.28M |
| EBITDA | 296.15M | 148.65M | -14.58M | -394.03M | 183.45M |
| Net Income | 70.79M | 52.18M | -45.79M | -424.78M | 132.59M |
Balance Sheet | |||||
| Total Assets | 918.52M | 655.32M | 398.25M | 431.75M | 394.65M |
| Cash, Cash Equivalents and Short-Term Investments | 185.57M | 43.58M | 22.00M | 34.26M | 36.12M |
| Total Debt | 351.39M | 340.30M | 275.76M | 267.20M | 178.55M |
| Total Liabilities | 495.09M | 453.43M | 319.14M | 311.42M | 203.07M |
| Stockholders Equity | 329.45M | 146.34M | 61.45M | 95.86M | 114.65M |
Cash Flow | |||||
| Free Cash Flow | 245.60M | 20.85M | -8.24M | 35.97M | 136.51M |
| Operating Cash Flow | 248.13M | 23.15M | 1.26M | 50.61M | 173.43M |
| Investing Cash Flow | -5.24M | -2.67M | -11.24M | -4.34M | -36.98M |
| Financing Cash Flow | -97.95M | 1.09M | -2.27M | -48.13M | -125.85M |
Clinigence Holdings Technical Analysis
Neutral
184.11
Price Trends
110.15
Negative
131.10
Negative
117.56
Negative
Market Momentum
-3.45
Negative
50.67
Neutral
72.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Neutral. The current price of 184.11 is above the 20-day moving average (MA) of 94.26, above the 50-day MA of 110.15, and above the 200-day MA of 117.56, indicating a neutral trend. The MACD of -3.45 indicates Negative momentum. The RSI at 50.67 is Neutral, neither overbought nor oversold. The STOCH value of 72.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NUTX.
Clinigence Holdings Risk Analysis
Clinigence Holdings disclosed 62 risk factors in its most recent earnings report. Clinigence Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clinigence Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $600.34M | 37.76 | 5.87% | 0.52% | 3.68% | 5.62% | |
64 Neutral | $703.25M | 15.58 | 23.80% | ― | 236.03% | ― | |
55 Neutral | $2.85B | -46.73 | -5.69% | ― | 1.92% | 59.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $154.24M | -2.20 | -47.69% | ― | -5.30% | 46.01% | |
45 Neutral | $251.19M | -0.85 | -69.22% | ― | -16.65% | -71.92% | |
43 Neutral | $86.10M | -0.94 | -30.28% | ― | 4.64% | -17.17% |
* Healthcare Sector Average
NUTX
Clinigence Holdings
100.92
25.53
33.86%
HSTM
HealthStream
20.45
-10.02
-32.89%
EVH
Evolent Health
2.25
-7.15
-76.06%
HCAT
Health Catalyst
1.17
-2.82
-70.68%
TXG
10x Genomics
22.33
14.75
194.59%
DH
Definitive Healthcare Corp
1.08
-1.43
-56.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.